| Drug General Information |
| Drug ID |
D01YWE
|
| Former ID |
DIB019450
|
| Drug Name |
compound 33
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[530078]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C17H14N4O4
|
| InChI |
InChI=1S/C17H14N4O4/c18-17(25)12(9-2-1-3-11(22)8-9)21-14-13(15(23)16(14)24)20-10-4-6-19-7-5-10/h1-8,12,21-22H,(H2,18,25)(H,19,20)
|
| InChIKey |
GPXKVULNYYNGDP-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Protein kinase A |
Target Info |
Inhibitor |
[530078]
|
|---|
| Serine/threonine-protein kinase Chk1 |
Target Info |
Inhibitor |
[530078]
|
| Rho-associated protein kinase 1 |
Target Info |
Inhibitor |
[530078]
|
| casein kinase 1, gamma 1 |
Target Info |
Inhibitor |
[530078]
|
| ribosomal protein S6 kinase, 90kDa, polypeptide 1 |
Target Info |
Inhibitor |
[530078]
|
| MAPKAP kinase 2 |
Target Info |
Inhibitor |
[530078]
|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
HTLV-I infection
|
|
Viral carcinogenesishsa04022:cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
TGF-beta signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Platelet activation
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Oxytocin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancerhsa04010:MAPK signaling pathway
|
|
VEGF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Viral carcinogenesis
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPase
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
CCKR signaling map STP00005:Angiogenesis
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
p38 MAPK pathway
|
|
Pathway Interaction Database
|
Fanconi anemia pathway
|
|
p73 transcription factor network
|
|
ATR signaling pathway
|
|
Circadian rhythm pathway
|
|
p53 pathwayprlsignalingeventspathway:Signaling events mediated by PRL
|
|
RhoA signaling pathway
|
|
Noncanonical Wnt signaling pathway
|
|
EPHB forward signaling
|
|
Thromboxane A2 receptor signaling
|
|
PAR4-mediated thrombin signaling events
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
EPHA forward signaling
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
N-cadherin signaling eventsil2_1pathway:IL2-mediated signaling events
|
|
p38 signaling mediated by MAPKAP kinases
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
Reactome
|
Activation of ATR in response to replication stress
|
|
Processing of DNA double-strand break ends
|
|
Presynaptic phase of homologous DNA pairing and strand exchange
|
|
G2/M DNA damage checkpoint
|
|
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexR-HSA-111465:Apoptotic cleavage of cellular proteins
|
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
G alpha (12/13) signalling events
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
RHO GTPases Activate ROCKsR-HSA-171007:p38MAPK events
|
|
Oxidative Stress Induced Senescence
|
|
Regulation of HSF1-mediated heat shock response
|
|
activated TAK1 mediates p38 MAPK activation
|
|
WikiPathways
|
DNA Damage Response
|
|
Signaling by SCF-KIT
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell Cycle
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage ResponseWP524:G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Focal Adhesion
|
|
JAK/STAT
|
|
AGE/RAGE pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Integrin-mediated Cell Adhesion
|
|
GPCR downstream signaling
|
|
Apoptotic execution phase
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathwayWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
p38 MAPK Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
FAS pathway and Stress induction of HSP regulation
|
|
MAP kinase activation in TLR cascade
|
|
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements
|
|
Arachidonic acid metabolism
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
IL-1 signaling pathway
|
|
NGF signalling via TRKA from the plasma membrane
|
|
MAPK targets/ Nuclear events mediated by MAP kinases
|
| References |
| Ref 530078 | Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. |
|---|
| Ref 530078 | Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. |
|---|
